Ehdaie Behfar, Smith Steven C, Theodorescu Dan
Department of Urology;
Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S232-6. doi: 10.5489/cuaj.1204.
The past decade has provided an improved understanding of the molecular mechanism of bladder cancer by defining distinct pathways in tumorigenesis and progression. Advances in technologies, such as high-throughput transcript profiling, microarrays and proteomics, offer a systematic approach to identifying targets for bladder cancer diagnostics and drug discovery. This review presents a select outline of the advances in the development of bio-markers and targets for patient prognosis and therapy selection. This paper describes a representative cohort of recent studies that have the potential to significantly impact the management of muscle invasive and metastatic urothelial carcinoma of the bladder. Space constraints do not permit this review to be comprehensive and we apologize to the authors whose work we do not cite.
在过去十年中，通过明确肿瘤发生和进展中的不同途径，人们对膀胱癌的分子机制有了更深入的了解。诸如高通量转录谱分析、微阵列和蛋白质组学等技术的进步，为识别膀胱癌诊断和药物研发的靶点提供了系统方法。本综述概述了生物标志物和靶点开发方面的进展，用于患者预后评估和治疗选择。本文描述了一组具有代表性的近期研究，这些研究有可能对肌肉浸润性和转移性膀胱尿路上皮癌的管理产生重大影响。由于篇幅限制，本综述无法做到全面涵盖，对于未引用其研究成果的作者，我们深表歉意。
